A compound of the formula (I):
wherein:
A and B together represent an optionally substituted, fused aromatic ring; X and Y are selected from CH and CH, CF and CH, CH and CF and N and CH respectively; RC is selected from H, C1-4 alkyl; and R1 is selected from C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl, which groups are optionally substituted; or RC and R1 together with the carbon and oxygen atoms to which they are attached form a spiro-C5-7 oxygen-containing heterocyclic group, which is optionally substituted or fused to a C5-7 aromatic ring.
化合物的式子(I):
其中:
A 和 B 一起代表一个可选取取代基的融合芳香环;
X 和 Y 分别从 CH 和 CH、CF 和 CH、CH 和 CF 和 N 和 CH 中选择;
RC 从 H、C1-4 烷基中选择;
R1 从 C1-7 烷基、C3-20 杂环基和 C5-20 芳基中选择,这些基团可选取取代基;或者 RC 和 R1 与它们附着的碳和氧原子一起形成一个螺环-C5-7 含氧杂环基,该基团可选取取代基或融合到一个 C5-7 芳香环中。
US8129380B2
申请人:——
公开号:US8129380B2
公开(公告)日:2012-03-06
[EN] PHTHALAZINONE DERIVATIVES<br/>[FR] DÉRIVÉS DE PHTALAZINONE
申请人:ASTRAZENECA AB
公开号:WO2009093032A1
公开(公告)日:2009-07-30
A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; X and Y are selected from CH and CH, CF and CH, CH and CF and N and CH respectively; Rc is selected from H, C1.4 alkyl; and R1 is selected from C1-7 alkyI, C3-20 heterocydyl and C5-20 aryl, which groups are optionally substituted; or Rc and R1 together with the carbon and oxygen atoms to which they are attached form a spiro-C5-7 oxygen-containing heterocyclic group, which is optionally substituted or fused to a C5-7 aromatic ring. These compounds are useful in the preparation of a medicament for inhibiting the activity of PARP for the treatment of : vascular disease; septic shock;ischaemic injury;neurotoxicity;haemorraghic shock;viral infection; or for use as an adjunct in cancer therapy or for potentiating tumour cells for treatment with ionizing radiation or chemotherapeutic agents.
PHTHALAZINONE DERIVATIVES
申请人:MENEAR Keith Allan
公开号:US20090192156A1
公开(公告)日:2009-07-30
A compound of the formula (I):
wherein:
A and B together represent an optionally substituted, fused aromatic ring; X and Y are selected from CH and CH, CF and CH, CH and CF and N and CH respectively; R
C
is selected from H, C
1-4
alkyl; and R
1
is selected from C
1-7
alkyl, C
3-20
heterocyclyl and C
5-20
aryl, which groups are optionally substituted; or R
C
and R
1
together with the carbon and oxygen atoms to which they are attached form a spiro-C
5-7
oxygen-containing heterocyclic group, which is optionally substituted or fused to a C
5-7
aromatic ring.